B. Riley Wealth Advisors’s XTL Biopharmaceuticals XTLB Stock Holding History

B. Riley Wealth Advisors’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-20	Closed	-$1.22K	–	1923
2014 Q2	$1.22K	Buy	+20	New	+$1.32K	﹤0.01%	2283

Other funds holding XTLB

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

B. Riley Wealth Advisors's XTLB Position: Q3 2014 in Review

B. Riley Wealth Advisors sold out of XTL Biopharmaceuticals (XTLB) in Q3 2014, closing a stake of 20 shares — an estimated $1.22K sold.

B. Riley Wealth Advisors first reported a position in XTLB in Q2 2014 and held it in 1 quarter. The position peaked at $1.22K in Q2 2014. 3 funds tracked by Wall St. Rank hold XTLB as of Q3 2014.

B. Riley Wealth Advisors reported no remaining XTL Biopharmaceuticals position as of Q3 2014 after selling out during the quarter.
B. Riley Wealth Advisors sold 20 XTL Biopharmaceuticals shares in Q3 2014, an estimated $1.22K.
B. Riley Wealth Advisors first reported a position in XTL Biopharmaceuticals in Q2 2014 and held it in 1 quarter.
B. Riley Wealth Advisors's XTL Biopharmaceuticals position peaked at $1.22K in Q2 2014.
3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q3 2014.

Based on B. Riley Wealth Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.